Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Apr 18, 2025
Date Accepted: Dec 2, 2025

The final, peer-reviewed published version of this preprint can be found here:

Therapeutic Effects of a WeChat Mini-Program on Metabolic Dysfunction–Associated Fatty Liver Disease: Randomized Controlled Trial

Sun C, Chen G, Shi C, Cao H, Yang R, Zeng J, Duan X, Sun X, Fan JG

Therapeutic Effects of a WeChat Mini-Program on Metabolic Dysfunction–Associated Fatty Liver Disease: Randomized Controlled Trial

J Med Internet Res 2026;28:e76204

DOI: 10.2196/76204

PMID: 41592277

PMCID: 12843888

Therapeutic effects of a WeChat mini-program on metabolic dysfunction-associated fatty liver disease: Randomized Controlled Trial

  • Chao Sun; 
  • Guangyu Chen; 
  • Cuicui Shi; 
  • Haixia Cao; 
  • Ruixu Yang; 
  • Jing Zeng; 
  • Xiaoyan Duan; 
  • Xin Sun; 
  • Jian-Gao Fan

ABSTRACT

Background:

Weight loss is the standard recommendation for patients with metabolic dysfunction-associated fatty liver disease (MAFLD), but its successful implementation is difficult in practice. Digital lifestyle interventions may provide an efficient and scalable solution to enhance patient self-management.

Objective:

This study aimed to assess the effects of a WeChat mini-program-delivered lifestyle intervention on weight loss and hepatic steatosis among overweight or obese individuals with MAFLD

Methods:

Overweight or obese adults with clinically diagnosed MAFLD with transient elastography examination were enrolled in this prospective randomized controlled trial. Patients were randomly assigned to receive either WeChat mini-program management (intervention group) or standard care (control group) at a 1:1 ratio. Body weight and clinical parameters were assessed at baseline and then at 6 months.

Results:

Among the 89 included MAFLD patients, 60.0% achieved ≥5% weight loss, and 24.4% had ≥10% weight loss in the intervention group, which were greater than those in the control group (P <0.05). Importantly, patients receiving the intervention were significantly more likely to achieve a ≥10% controlled attenuation parameter (CAP)reduction or CAP normalization than those in the control group were (57.8% vs. 31.8%, P <0.05). In parallel, the intervention group presented greater reductions in liver enzymes (ALT, AST, and GGT) and metabolic parameters (fasting insulin, HbA1c, TG, and HDL-C) than the control group (P <0.05). According to the fibrosis assessment, only the FibroScan-aspartate aminotransferase (FAST) score decreased more in the intervention group than in the control group (P <0.05). No significant difference was found in the liver stiffness measurement (LSM) values or noninvasive scores (APRI, FIB-4, NFS, and Agile 3+) between the groups (P>0.05).

Conclusions:

Digital lifestyle coaching via a WeChat mini-program demonstrates efficacy in enhancing weight reduction, improving hepatic steatosis, and ameliorating metabolic disorders, offering novel perspectives regarding the practicality and therapeutic value of digital tools in managing MAFLD through behavioral interventions. Clinical Trial: Chinese Clinical Trial Registry ChiCTR2500100197; https://www.chictr.org.cn/


 Citation

Please cite as:

Sun C, Chen G, Shi C, Cao H, Yang R, Zeng J, Duan X, Sun X, Fan JG

Therapeutic Effects of a WeChat Mini-Program on Metabolic Dysfunction–Associated Fatty Liver Disease: Randomized Controlled Trial

J Med Internet Res 2026;28:e76204

DOI: 10.2196/76204

PMID: 41592277

PMCID: 12843888

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.